EGFR and cancer: In this study, we have shown that B-ASO is efficiently taken up by EGFR-FESAN in EGFR-overexpressing cancer cells and has higher anti-EGFR silencing activity than it has in case of delivery by the commercial Lipofectamine 2000 transfection agent.